ChoA Pharmaceutical Co., Ltd. announced that it expects to receive KRW 12 billion in funding from Moorim Capital Co., Ltd., Dongbu Securities Co., Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm and other investors
October 20, 2017
Share
ChoA Pharmaceutical Co., Ltd. (KOSDAQ:A034940) announce a private placement of 3rd series unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 12,000,000,000 on October 24, 2017. The transaction will include participation from Moorim Capital Co., Ltd., Dongbu Securities Co., Ltd. for KRW 2,000,000,000 , Investment Arm for KRW 4,500,000,000, NH Investment & Securities Co., Ltd. (From the position of a Trust agent of “fund 1”) for KRW 3,000,000,000. The bonds will be issued at par and does not carry any coupon. The bonds would mature on April 24, 2022. The Bonds are fully convertible into 2,733,485 common shares between the periods of October 24, 2018 to March 24, 2022 at a fixed conversion price of KRW 4,390 per share. The transaction was approval from board of directors of the company. The subscription date is October 24, 2017.
CHOA PHARMACEUTICAL CO,.LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products are mainly for treatment of indigestion, gastric ulcer, duodenal ulcer, gastritis, gastric hyperacidity, intestinal disorder, constipation, diarrhea, stomachache, calcium deficiency, fatigue, iron deficiency anemia, neurasthenia, hypertension, hyperlipidemia, circulatory disorder, medicine poisoning, hepatic disease, allergic rhinitis, cough, cold, rheumatoid arthritis and others. It also provides nutrition products, health drinks, mixed drinks, beverages for children, cosmetics and others.
ChoA Pharmaceutical Co., Ltd. announced that it expects to receive KRW 12 billion in funding from Moorim Capital Co., Ltd., Dongbu Securities Co., Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm and other investors
CHOA PHARMACEUTICAL CO., LTD. 
